Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mechanisms of action of PDE5 inhibition in erectile dysfunction

Abstract

A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  1. Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.

    CAS  Google Scholar 

  2. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ . Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257–261.

    Article  CAS  Google Scholar 

  3. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–94.

    Article  CAS  Google Scholar 

  4. Trigo-Rocha F et al. Intracellular mechanism of penile erection in monkeys. Neurourol Urodyn 1994; 13: 71–80.

    Article  CAS  Google Scholar 

  5. Chuang T, Strauss JD, Murphy RA, Steers WD . Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 1998; 160: 257–261.

    Article  CAS  Google Scholar 

  6. Beavo JA . Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725–748.

    Article  CAS  Google Scholar 

  7. Fisher DA et al. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 1998; 246: 570–577.

    Article  CAS  Google Scholar 

  8. Soderling SH, Bayuga SJ, Beavo JA . Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998; 273: 15553–15558.

    Article  CAS  Google Scholar 

  9. Fawcett L et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000; 97: 3702–3707.

    Article  CAS  Google Scholar 

  10. Kuthe A et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 2001; 165: 280–283.

    Article  CAS  Google Scholar 

  11. Fink TL et al. Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 1999; 274: 34613–34620.

    Article  CAS  Google Scholar 

  12. Thomas MK, Francis SH, Corbin JD . Substrate-and-kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 1990; 265: 124971–124978.

    Google Scholar 

  13. Liu L et al. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal 2002; 14: 45–51.

    Article  Google Scholar 

  14. Gopal VK, Francis SH, Corbin JD . Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 2001; 268: 3304–3312.

    Article  CAS  Google Scholar 

  15. Corbin JD, Turko IV, Beasley A, Francis SH . Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000; 267: 2760–2767.

    Article  CAS  Google Scholar 

  16. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD . ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 1998; 274: H448–H455.

    CAS  PubMed  Google Scholar 

  17. Rybalkin SD et al. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310–3317.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J D Corbin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Corbin, J. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 (Suppl 1), S4–S7 (2004). https://doi.org/10.1038/sj.ijir.3901205

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901205

Keywords

  • phosphodiesterase inhibitors
  • vasodilator agents
  • cyclic GMP
  • impotence
  • penile erection

This article is cited by

Search

Quick links